EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, ILL – AbbVie (NYSE:… Read More
It was an exciting night for glycomics at the 2024 ASTech Awards Gala on November 1 with two awards going to members of the GlycoNet community: startup PanTHERA CryoSolutions and… Read More
UBC Faculty of Medicine professor Dr. Laura Sly and her team are accelerating the development of innovative new drugs for patients with inflammatory bowel disease (IBD) thanks to the support… Read More
mRESVIA™ is Moderna’s second approved product in Canada and is the first mRNA vaccine for RSV and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to… Read More
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and… Read More
